Global Clinical Trial 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01251253

Publication Date:

January 9, 2025

Pages:

101

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Clinical Trial market size is predicted to grow from US$ 53980 million in 2025 to US$ 91170 million in 2031; it is expected to grow at a CAGR of 9.1% from 2025 to 2031.
Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial 鈥� their approval does not mean that the therapy is "safe" or effective, only that the trial may be conducted.
The industry"s leading producers are Parexel, PRA Health and LabCorp (Covance), which accounted for 4.94%, 7.25% and 11.81% of revenue in 2019, respectively. By region, North America has the highest share of income, at more than 39 percent.
The 鈥淐linical Trial Industry Forecast鈥� looks at past sales and reviews total world Clinical Trial sales in 2024, providing a comprehensive analysis by region and market sector of projected Clinical Trial sales for 2025 through 2031. With Clinical Trial sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Clinical Trial industry.
This Insight Report provides a comprehensive analysis of the global Clinical Trial landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Clinical Trial portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Clinical Trial market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Clinical Trial and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Clinical Trial.
This report presents a comprehensive overview, market shares, and growth opportunities of Clinical Trial market by product type, application, key players and key regions and countries.
Segmentation by Type:
Instruments(Products)
Consumables
Others
Segmentation by Application:
Procurement and Supplies
Rentals
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Fisher Clinical Services
Myoderm
Bilcare
CliniChain
Ancillare
MESM
ERG Holding
Apex Medical Research
Parexel
PRA Health
LabCorp (Covance)
Marken
AmerisourceBergen (World Courier)

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Clinical Trial 麻豆原创 Size (2020-2031)
2.1.2 Clinical Trial 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Clinical Trial by Country/Region (2020, 2024 & 2031)
2.2 Clinical Trial Segment by Type
2.2.1 Instruments(Products)
2.2.2 Consumables
2.2.3 Others
2.3 Clinical Trial 麻豆原创 Size by Type
2.3.1 Clinical Trial 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Clinical Trial 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Clinical Trial Segment by Application
2.4.1 Procurement and Supplies
2.4.2 Rentals
2.4.3 Others
2.5 Clinical Trial 麻豆原创 Size by Application
2.5.1 Clinical Trial 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Clinical Trial 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Clinical Trial 麻豆原创 Size by Player
3.1 Clinical Trial 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Clinical Trial Revenue by Player (2020-2025)
3.1.2 Global Clinical Trial Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Clinical Trial Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Clinical Trial by Region
4.1 Clinical Trial 麻豆原创 Size by Region (2020-2025)
4.2 Global Clinical Trial Annual Revenue by Country/Region (2020-2025)
4.3 Americas Clinical Trial 麻豆原创 Size Growth (2020-2025)
4.4 APAC Clinical Trial 麻豆原创 Size Growth (2020-2025)
4.5 Europe Clinical Trial 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Clinical Trial 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Clinical Trial 麻豆原创 Size by Country (2020-2025)
5.2 Americas Clinical Trial 麻豆原创 Size by Type (2020-2025)
5.3 Americas Clinical Trial 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Clinical Trial 麻豆原创 Size by Region (2020-2025)
6.2 APAC Clinical Trial 麻豆原创 Size by Type (2020-2025)
6.3 APAC Clinical Trial 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Clinical Trial 麻豆原创 Size by Country (2020-2025)
7.2 Europe Clinical Trial 麻豆原创 Size by Type (2020-2025)
7.3 Europe Clinical Trial 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Clinical Trial by Region (2020-2025)
8.2 Middle East & Africa Clinical Trial 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Clinical Trial 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Clinical Trial 麻豆原创 Forecast
10.1 Global Clinical Trial Forecast by Region (2026-2031)
10.1.1 Global Clinical Trial Forecast by Region (2026-2031)
10.1.2 Americas Clinical Trial Forecast
10.1.3 APAC Clinical Trial Forecast
10.1.4 Europe Clinical Trial Forecast
10.1.5 Middle East & Africa Clinical Trial Forecast
10.2 Americas Clinical Trial Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Clinical Trial Forecast
10.2.2 Canada 麻豆原创 Clinical Trial Forecast
10.2.3 Mexico 麻豆原创 Clinical Trial Forecast
10.2.4 Brazil 麻豆原创 Clinical Trial Forecast
10.3 APAC Clinical Trial Forecast by Region (2026-2031)
10.3.1 China Clinical Trial 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Clinical Trial Forecast
10.3.3 Korea 麻豆原创 Clinical Trial Forecast
10.3.4 Southeast Asia 麻豆原创 Clinical Trial Forecast
10.3.5 India 麻豆原创 Clinical Trial Forecast
10.3.6 Australia 麻豆原创 Clinical Trial Forecast
10.4 Europe Clinical Trial Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Clinical Trial Forecast
10.4.2 France 麻豆原创 Clinical Trial Forecast
10.4.3 UK 麻豆原创 Clinical Trial Forecast
10.4.4 Italy 麻豆原创 Clinical Trial Forecast
10.4.5 Russia 麻豆原创 Clinical Trial Forecast
10.5 Middle East & Africa Clinical Trial Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Clinical Trial Forecast
10.5.2 South Africa 麻豆原创 Clinical Trial Forecast
10.5.3 Israel 麻豆原创 Clinical Trial Forecast
10.5.4 Turkey 麻豆原创 Clinical Trial Forecast
10.6 Global Clinical Trial Forecast by Type (2026-2031)
10.7 Global Clinical Trial Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Clinical Trial Forecast
11 Key Players Analysis
11.1 Fisher Clinical Services
11.1.1 Fisher Clinical Services Company Information
11.1.2 Fisher Clinical Services Clinical Trial Product Offered
11.1.3 Fisher Clinical Services Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Fisher Clinical Services Main Business Overview
11.1.5 Fisher Clinical Services Latest Developments
11.2 Myoderm
11.2.1 Myoderm Company Information
11.2.2 Myoderm Clinical Trial Product Offered
11.2.3 Myoderm Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Myoderm Main Business Overview
11.2.5 Myoderm Latest Developments
11.3 Bilcare
11.3.1 Bilcare Company Information
11.3.2 Bilcare Clinical Trial Product Offered
11.3.3 Bilcare Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Bilcare Main Business Overview
11.3.5 Bilcare Latest Developments
11.4 CliniChain
11.4.1 CliniChain Company Information
11.4.2 CliniChain Clinical Trial Product Offered
11.4.3 CliniChain Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 CliniChain Main Business Overview
11.4.5 CliniChain Latest Developments
11.5 Ancillare
11.5.1 Ancillare Company Information
11.5.2 Ancillare Clinical Trial Product Offered
11.5.3 Ancillare Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Ancillare Main Business Overview
11.5.5 Ancillare Latest Developments
11.6 MESM
11.6.1 MESM Company Information
11.6.2 MESM Clinical Trial Product Offered
11.6.3 MESM Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 MESM Main Business Overview
11.6.5 MESM Latest Developments
11.7 ERG Holding
11.7.1 ERG Holding Company Information
11.7.2 ERG Holding Clinical Trial Product Offered
11.7.3 ERG Holding Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 ERG Holding Main Business Overview
11.7.5 ERG Holding Latest Developments
11.8 Apex Medical Research
11.8.1 Apex Medical Research Company Information
11.8.2 Apex Medical Research Clinical Trial Product Offered
11.8.3 Apex Medical Research Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Apex Medical Research Main Business Overview
11.8.5 Apex Medical Research Latest Developments
11.9 Parexel
11.9.1 Parexel Company Information
11.9.2 Parexel Clinical Trial Product Offered
11.9.3 Parexel Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Parexel Main Business Overview
11.9.5 Parexel Latest Developments
11.10 PRA Health
11.10.1 PRA Health Company Information
11.10.2 PRA Health Clinical Trial Product Offered
11.10.3 PRA Health Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 PRA Health Main Business Overview
11.10.5 PRA Health Latest Developments
11.11 LabCorp (Covance)
11.11.1 LabCorp (Covance) Company Information
11.11.2 LabCorp (Covance) Clinical Trial Product Offered
11.11.3 LabCorp (Covance) Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 LabCorp (Covance) Main Business Overview
11.11.5 LabCorp (Covance) Latest Developments
11.12 Marken
11.12.1 Marken Company Information
11.12.2 Marken Clinical Trial Product Offered
11.12.3 Marken Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Marken Main Business Overview
11.12.5 Marken Latest Developments
11.13 AmerisourceBergen (World Courier)
11.13.1 AmerisourceBergen (World Courier) Company Information
11.13.2 AmerisourceBergen (World Courier) Clinical Trial Product Offered
11.13.3 AmerisourceBergen (World Courier) Clinical Trial Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 AmerisourceBergen (World Courier) Main Business Overview
11.13.5 AmerisourceBergen (World Courier) Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.